Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Identifieur interne : 002007 ( Main/Exploration ); précédent : 002006; suivant : 002008Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Auteurs : Vlad Ratziu [France] ; Stephen A. Harrison [États-Unis] ; Sven Francque [Belgique] ; Pierre Bedossa [France] ; Philippe Lehert [Belgique] ; Lawrence Serfaty [France] ; Manuel Romero-Gomez ; Jérôme Boursier [France] ; Manal Abdelmalek [États-Unis] ; Steve Caldwell [États-Unis] ; Joost Drenth [Pays-Bas] ; Quentin M. Anstee [Royaume-Uni] ; Dean Hum [France] ; Remy Hanf [France] ; Alice Roudot [France] ; Sophie Megnien [France] ; Bart Staels [France] ; Arun Sanyal [États-Unis]Source :
- Gastroenterology [ 1528-0012 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Agents gastro-intestinaux (administration et posologie), Agents gastro-intestinaux (effets indésirables), Analyse de l'intention de traiter, Biopsie, Chalcones (administration et posologie), Chalcones (effets indésirables), Cirrhose du foie (étiologie), Europe, Facteurs temps, Femelle, Foie (), Foie (anatomopathologie), Foie (métabolisme), Humains, Indice de gravité médicale, Induction de rémission, Marqueurs biologiques (sang), Modèles logistiques, Mâle, Méthode en double aveugle, Odds ratio, Propionates (administration et posologie), Propionates (effets indésirables), Récepteur PPAR alpha (agonistes), Récepteur PPAR alpha (métabolisme), Récepteur PPAR gamma (agonistes), Récepteur PPAR gamma (métabolisme), Résultat thérapeutique, Stéatose hépatique non alcoolique (), Stéatose hépatique non alcoolique (anatomopathologie), Stéatose hépatique non alcoolique (métabolisme), Stéatose hépatique non alcoolique (traitement médicamenteux), Transduction du signal (), États-Unis d'Amérique.
- MESH :
- administration et posologie : Agents gastro-intestinaux, Chalcones, Propionates.
- agonistes : Récepteur PPAR alpha, Récepteur PPAR gamma.
- anatomopathologie : Foie, Stéatose hépatique non alcoolique.
- effets indésirables : Agents gastro-intestinaux, Chalcones, Propionates.
- métabolisme : Foie, Récepteur PPAR alpha, Récepteur PPAR gamma, Stéatose hépatique non alcoolique.
- sang : Marqueurs biologiques.
- traitement médicamenteux : Stéatose hépatique non alcoolique.
- étiologie : Cirrhose du foie.
- Adulte, Adulte d'âge moyen, Analyse de l'intention de traiter, Biopsie, Europe, Facteurs temps, Femelle, Foie, Humains, Indice de gravité médicale, Induction de rémission, Modèles logistiques, Mâle, Méthode en double aveugle, Odds ratio, Résultat thérapeutique, Stéatose hépatique non alcoolique, Transduction du signal, États-Unis d'Amérique.
English descriptors
- KwdEn :
- Adult, Biomarkers (blood), Biopsy, Chalcones (administration & dosage), Chalcones (adverse effects), Double-Blind Method, Europe, Female, Gastrointestinal Agents (administration & dosage), Gastrointestinal Agents (adverse effects), Humans, Intention to Treat Analysis, Liver (drug effects), Liver (metabolism), Liver (pathology), Liver Cirrhosis (etiology), Logistic Models, Male, Middle Aged, Non-alcoholic Fatty Liver Disease (complications), Non-alcoholic Fatty Liver Disease (drug therapy), Non-alcoholic Fatty Liver Disease (metabolism), Non-alcoholic Fatty Liver Disease (pathology), Odds Ratio, PPAR alpha (agonists), PPAR alpha (metabolism), PPAR gamma (agonists), PPAR gamma (metabolism), Propionates (administration & dosage), Propionates (adverse effects), Remission Induction, Severity of Illness Index, Signal Transduction (drug effects), Time Factors, Treatment Outcome, United States.
- MESH :
- chemical , administration & dosage : Chalcones, Gastrointestinal Agents, Propionates.
- chemical , adverse effects : Chalcones, Gastrointestinal Agents, Propionates.
- chemical , agonists : PPAR alpha, PPAR gamma.
- chemical , blood : Biomarkers.
- complications : Non-alcoholic Fatty Liver Disease.
- drug effects : Liver, Signal Transduction.
- drug therapy : Non-alcoholic Fatty Liver Disease.
- etiology : Liver Cirrhosis.
- metabolism : Liver, Non-alcoholic Fatty Liver Disease, PPAR alpha, PPAR gamma.
- pathology : Liver, Non-alcoholic Fatty Liver Disease.
- Adult, Biopsy, Double-Blind Method, Europe, Female, Humans, Intention to Treat Analysis, Logistic Models, Male, Middle Aged, Odds Ratio, Remission Induction, Severity of Illness Index, Time Factors, Treatment Outcome, United States.
Abstract
Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).
DOI: 10.1053/j.gastro.2016.01.038
PubMed: 26874076
Affiliations:
- Belgique, France, Pays-Bas, Royaume-Uni, États-Unis
- Caroline du Nord, Gueldre, Hauts-de-France, Nord-Pas-de-Calais, Pays de la Loire, Texas, Victoria (État), Virginie, Île-de-France
- Angers, Lille, Melbourne, Nimègue, Paris
- Université Pierre-et-Marie-Curie, Université de Melbourne
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001F51
- to stream PubMed, to step Curation: 001F27
- to stream PubMed, to step Checkpoint: 001F27
- to stream Ncbi, to step Merge: 003129
- to stream Ncbi, to step Curation: 003129
- to stream Ncbi, to step Checkpoint: 003129
- to stream Main, to step Merge: 002006
- to stream Main, to step Curation: 002007
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.</title><author><name sortKey="Ratziu, Vlad" sort="Ratziu, Vlad" uniqKey="Ratziu V" first="Vlad" last="Ratziu">Vlad Ratziu</name><affiliation wicri:level="4"><nlm:affiliation>Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France; Institute of Cardiometabolism and Nutrition, INSERM, UMRS 938, Paris, France. Electronic address: vlad.ratziu@upmc.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France; Institute of Cardiometabolism and Nutrition, INSERM, UMRS 938, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Pierre-et-Marie-Curie</orgName></affiliation></author><author><name sortKey="Harrison, Stephen A" sort="Harrison, Stephen A" uniqKey="Harrison S" first="Stephen A" last="Harrison">Stephen A. Harrison</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston</wicri:cityArea></affiliation></author><author><name sortKey="Francque, Sven" sort="Francque, Sven" uniqKey="Francque S" first="Sven" last="Francque">Sven Francque</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp</wicri:regionArea><wicri:noRegion>Antwerp</wicri:noRegion></affiliation></author><author><name sortKey="Bedossa, Pierre" sort="Bedossa, Pierre" uniqKey="Bedossa P" first="Pierre" last="Bedossa">Pierre Bedossa</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, Hôpital Beaujon, University Paris-Denis Diderot, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Pathology, Hôpital Beaujon, University Paris-Denis Diderot, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name><affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, the University of Melbourne, Melbourne, Australia; Faculty of Economics, University of Louvain UCL, Belgique, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Psychiatry, the University of Melbourne, Melbourne, Australia; Faculty of Economics, University of Louvain UCL, Belgique</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Serfaty, Lawrence" sort="Serfaty, Lawrence" uniqKey="Serfaty L" first="Lawrence" last="Serfaty">Lawrence Serfaty</name><affiliation wicri:level="4"><nlm:affiliation>Université Pierre et Marie Curie, Hôpital Saint-Antoine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Pierre et Marie Curie, Hôpital Saint-Antoine, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Pierre-et-Marie-Curie</orgName></affiliation></author><author><name sortKey="Romero Gomez, Manuel" sort="Romero Gomez, Manuel" uniqKey="Romero Gomez M" first="Manuel" last="Romero-Gomez">Manuel Romero-Gomez</name><affiliation><nlm:affiliation>Unit for the Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Sevilla.</nlm:affiliation><wicri:noCountry code="subField">Sevilla</wicri:noCountry></affiliation></author><author><name sortKey="Boursier, Jerome" sort="Boursier, Jerome" uniqKey="Boursier J" first="Jérôme" last="Boursier">Jérôme Boursier</name><affiliation wicri:level="3"><nlm:affiliation>Hepatology Department, University Hospital and LUNAM University, Angers, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hepatology Department, University Hospital and LUNAM University, Angers</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Angers</settlement></placeName></affiliation></author><author><name sortKey="Abdelmalek, Manal" sort="Abdelmalek, Manal" uniqKey="Abdelmalek M" first="Manal" last="Abdelmalek">Manal Abdelmalek</name><affiliation wicri:level="2"><nlm:affiliation>Duke University, Durham, North Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Duke University, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Caldwell, Steve" sort="Caldwell, Steve" uniqKey="Caldwell S" first="Steve" last="Caldwell">Steve Caldwell</name><affiliation wicri:level="2"><nlm:affiliation>Gastroenterology and Hepatology Division, University of Virginia, Charlottesville, Virginia.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>Gastroenterology and Hepatology Division, University of Virginia, Charlottesville</wicri:cityArea></affiliation></author><author><name sortKey="Drenth, Joost" sort="Drenth, Joost" uniqKey="Drenth J" first="Joost" last="Drenth">Joost Drenth</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen</wicri:regionArea><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Anstee, Quentin M" sort="Anstee, Quentin M" uniqKey="Anstee Q" first="Quentin M" last="Anstee">Quentin M. Anstee</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>Newcastle upon Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Hum, Dean" sort="Hum, Dean" uniqKey="Hum D" first="Dean" last="Hum">Dean Hum</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Hanf, Remy" sort="Hanf, Remy" uniqKey="Hanf R" first="Remy" last="Hanf">Remy Hanf</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Roudot, Alice" sort="Roudot, Alice" uniqKey="Roudot A" first="Alice" last="Roudot">Alice Roudot</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Megnien, Sophie" sort="Megnien, Sophie" uniqKey="Megnien S" first="Sophie" last="Megnien">Sophie Megnien</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Staels, Bart" sort="Staels, Bart" uniqKey="Staels B" first="Bart" last="Staels">Bart Staels</name><affiliation wicri:level="3"><nlm:affiliation>University of Lille, INSERM UMR1011, Institut Pasteur de Lille, European Genomic Institute for Diabetes, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Lille, INSERM UMR1011, Institut Pasteur de Lille, European Genomic Institute for Diabetes, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Sanyal, Arun" sort="Sanyal, Arun" uniqKey="Sanyal A" first="Arun" last="Sanyal">Arun Sanyal</name><affiliation wicri:level="2"><nlm:affiliation>Virginia Commonwealth University, Richmond, Virginia.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>Virginia Commonwealth University, Richmond</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26874076</idno><idno type="pmid">26874076</idno><idno type="doi">10.1053/j.gastro.2016.01.038</idno><idno type="wicri:Area/PubMed/Corpus">001F51</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F51</idno><idno type="wicri:Area/PubMed/Curation">001F27</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001F27</idno><idno type="wicri:Area/PubMed/Checkpoint">001F27</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001F27</idno><idno type="wicri:Area/Ncbi/Merge">003129</idno><idno type="wicri:Area/Ncbi/Curation">003129</idno><idno type="wicri:Area/Ncbi/Checkpoint">003129</idno><idno type="wicri:Area/Main/Merge">002006</idno><idno type="wicri:Area/Main/Curation">002007</idno><idno type="wicri:Area/Main/Exploration">002007</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.</title><author><name sortKey="Ratziu, Vlad" sort="Ratziu, Vlad" uniqKey="Ratziu V" first="Vlad" last="Ratziu">Vlad Ratziu</name><affiliation wicri:level="4"><nlm:affiliation>Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France; Institute of Cardiometabolism and Nutrition, INSERM, UMRS 938, Paris, France. Electronic address: vlad.ratziu@upmc.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France; Institute of Cardiometabolism and Nutrition, INSERM, UMRS 938, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Pierre-et-Marie-Curie</orgName></affiliation></author><author><name sortKey="Harrison, Stephen A" sort="Harrison, Stephen A" uniqKey="Harrison S" first="Stephen A" last="Harrison">Stephen A. Harrison</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston</wicri:cityArea></affiliation></author><author><name sortKey="Francque, Sven" sort="Francque, Sven" uniqKey="Francque S" first="Sven" last="Francque">Sven Francque</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp</wicri:regionArea><wicri:noRegion>Antwerp</wicri:noRegion></affiliation></author><author><name sortKey="Bedossa, Pierre" sort="Bedossa, Pierre" uniqKey="Bedossa P" first="Pierre" last="Bedossa">Pierre Bedossa</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, Hôpital Beaujon, University Paris-Denis Diderot, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Pathology, Hôpital Beaujon, University Paris-Denis Diderot, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name><affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, the University of Melbourne, Melbourne, Australia; Faculty of Economics, University of Louvain UCL, Belgique, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Psychiatry, the University of Melbourne, Melbourne, Australia; Faculty of Economics, University of Louvain UCL, Belgique</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Serfaty, Lawrence" sort="Serfaty, Lawrence" uniqKey="Serfaty L" first="Lawrence" last="Serfaty">Lawrence Serfaty</name><affiliation wicri:level="4"><nlm:affiliation>Université Pierre et Marie Curie, Hôpital Saint-Antoine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Pierre et Marie Curie, Hôpital Saint-Antoine, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Pierre-et-Marie-Curie</orgName></affiliation></author><author><name sortKey="Romero Gomez, Manuel" sort="Romero Gomez, Manuel" uniqKey="Romero Gomez M" first="Manuel" last="Romero-Gomez">Manuel Romero-Gomez</name><affiliation><nlm:affiliation>Unit for the Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Sevilla.</nlm:affiliation><wicri:noCountry code="subField">Sevilla</wicri:noCountry></affiliation></author><author><name sortKey="Boursier, Jerome" sort="Boursier, Jerome" uniqKey="Boursier J" first="Jérôme" last="Boursier">Jérôme Boursier</name><affiliation wicri:level="3"><nlm:affiliation>Hepatology Department, University Hospital and LUNAM University, Angers, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hepatology Department, University Hospital and LUNAM University, Angers</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Angers</settlement></placeName></affiliation></author><author><name sortKey="Abdelmalek, Manal" sort="Abdelmalek, Manal" uniqKey="Abdelmalek M" first="Manal" last="Abdelmalek">Manal Abdelmalek</name><affiliation wicri:level="2"><nlm:affiliation>Duke University, Durham, North Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Duke University, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Caldwell, Steve" sort="Caldwell, Steve" uniqKey="Caldwell S" first="Steve" last="Caldwell">Steve Caldwell</name><affiliation wicri:level="2"><nlm:affiliation>Gastroenterology and Hepatology Division, University of Virginia, Charlottesville, Virginia.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>Gastroenterology and Hepatology Division, University of Virginia, Charlottesville</wicri:cityArea></affiliation></author><author><name sortKey="Drenth, Joost" sort="Drenth, Joost" uniqKey="Drenth J" first="Joost" last="Drenth">Joost Drenth</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen</wicri:regionArea><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Anstee, Quentin M" sort="Anstee, Quentin M" uniqKey="Anstee Q" first="Quentin M" last="Anstee">Quentin M. Anstee</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>Newcastle upon Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Hum, Dean" sort="Hum, Dean" uniqKey="Hum D" first="Dean" last="Hum">Dean Hum</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Hanf, Remy" sort="Hanf, Remy" uniqKey="Hanf R" first="Remy" last="Hanf">Remy Hanf</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Roudot, Alice" sort="Roudot, Alice" uniqKey="Roudot A" first="Alice" last="Roudot">Alice Roudot</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Megnien, Sophie" sort="Megnien, Sophie" uniqKey="Megnien S" first="Sophie" last="Megnien">Sophie Megnien</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Staels, Bart" sort="Staels, Bart" uniqKey="Staels B" first="Bart" last="Staels">Bart Staels</name><affiliation wicri:level="3"><nlm:affiliation>University of Lille, INSERM UMR1011, Institut Pasteur de Lille, European Genomic Institute for Diabetes, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Lille, INSERM UMR1011, Institut Pasteur de Lille, European Genomic Institute for Diabetes, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Sanyal, Arun" sort="Sanyal, Arun" uniqKey="Sanyal A" first="Arun" last="Sanyal">Arun Sanyal</name><affiliation wicri:level="2"><nlm:affiliation>Virginia Commonwealth University, Richmond, Virginia.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>Virginia Commonwealth University, Richmond</wicri:cityArea></affiliation></author></analytic><series><title level="j">Gastroenterology</title><idno type="eISSN">1528-0012</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Biomarkers (blood)</term><term>Biopsy</term><term>Chalcones (administration & dosage)</term><term>Chalcones (adverse effects)</term><term>Double-Blind Method</term><term>Europe</term><term>Female</term><term>Gastrointestinal Agents (administration & dosage)</term><term>Gastrointestinal Agents (adverse effects)</term><term>Humans</term><term>Intention to Treat Analysis</term><term>Liver (drug effects)</term><term>Liver (metabolism)</term><term>Liver (pathology)</term><term>Liver Cirrhosis (etiology)</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Non-alcoholic Fatty Liver Disease (complications)</term><term>Non-alcoholic Fatty Liver Disease (drug therapy)</term><term>Non-alcoholic Fatty Liver Disease (metabolism)</term><term>Non-alcoholic Fatty Liver Disease (pathology)</term><term>Odds Ratio</term><term>PPAR alpha (agonists)</term><term>PPAR alpha (metabolism)</term><term>PPAR gamma (agonists)</term><term>PPAR gamma (metabolism)</term><term>Propionates (administration & dosage)</term><term>Propionates (adverse effects)</term><term>Remission Induction</term><term>Severity of Illness Index</term><term>Signal Transduction (drug effects)</term><term>Time Factors</term><term>Treatment Outcome</term><term>United States</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Agents gastro-intestinaux (administration et posologie)</term><term>Agents gastro-intestinaux (effets indésirables)</term><term>Analyse de l'intention de traiter</term><term>Biopsie</term><term>Chalcones (administration et posologie)</term><term>Chalcones (effets indésirables)</term><term>Cirrhose du foie (étiologie)</term><term>Europe</term><term>Facteurs temps</term><term>Femelle</term><term>Foie ()</term><term>Foie (anatomopathologie)</term><term>Foie (métabolisme)</term><term>Humains</term><term>Indice de gravité médicale</term><term>Induction de rémission</term><term>Marqueurs biologiques (sang)</term><term>Modèles logistiques</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Odds ratio</term><term>Propionates (administration et posologie)</term><term>Propionates (effets indésirables)</term><term>Récepteur PPAR alpha (agonistes)</term><term>Récepteur PPAR alpha (métabolisme)</term><term>Récepteur PPAR gamma (agonistes)</term><term>Récepteur PPAR gamma (métabolisme)</term><term>Résultat thérapeutique</term><term>Stéatose hépatique non alcoolique ()</term><term>Stéatose hépatique non alcoolique (anatomopathologie)</term><term>Stéatose hépatique non alcoolique (métabolisme)</term><term>Stéatose hépatique non alcoolique (traitement médicamenteux)</term><term>Transduction du signal ()</term><term>États-Unis d'Amérique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Chalcones</term><term>Gastrointestinal Agents</term><term>Propionates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Chalcones</term><term>Gastrointestinal Agents</term><term>Propionates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>PPAR alpha</term><term>PPAR gamma</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents gastro-intestinaux</term><term>Chalcones</term><term>Propionates</term></keywords><keywords scheme="MESH" qualifier="agonistes" xml:lang="fr"><term>Récepteur PPAR alpha</term><term>Récepteur PPAR gamma</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Foie</term><term>Stéatose hépatique non alcoolique</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Non-alcoholic Fatty Liver Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Liver</term><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Non-alcoholic Fatty Liver Disease</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agents gastro-intestinaux</term><term>Chalcones</term><term>Propionates</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Liver Cirrhosis</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Liver</term><term>Non-alcoholic Fatty Liver Disease</term><term>PPAR alpha</term><term>PPAR gamma</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Foie</term><term>Récepteur PPAR alpha</term><term>Récepteur PPAR gamma</term><term>Stéatose hépatique non alcoolique</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Liver</term><term>Non-alcoholic Fatty Liver Disease</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Marqueurs biologiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Stéatose hépatique non alcoolique</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Cirrhose du foie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Biopsy</term><term>Double-Blind Method</term><term>Europe</term><term>Female</term><term>Humans</term><term>Intention to Treat Analysis</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Remission Induction</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term><term>United States</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de l'intention de traiter</term><term>Biopsie</term><term>Europe</term><term>Facteurs temps</term><term>Femelle</term><term>Foie</term><term>Humains</term><term>Indice de gravité médicale</term><term>Induction de rémission</term><term>Modèles logistiques</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Odds ratio</term><term>Résultat thérapeutique</term><term>Stéatose hépatique non alcoolique</term><term>Transduction du signal</term><term>États-Unis d'Amérique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).</div></front></TEI><affiliations><list><country><li>Belgique</li><li>France</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Caroline du Nord</li><li>Gueldre</li><li>Hauts-de-France</li><li>Nord-Pas-de-Calais</li><li>Pays de la Loire</li><li>Texas</li><li>Victoria (État)</li><li>Virginie</li><li>Île-de-France</li></region><settlement><li>Angers</li><li>Lille</li><li>Melbourne</li><li>Nimègue</li><li>Paris</li></settlement><orgName><li>Université Pierre-et-Marie-Curie</li><li>Université de Melbourne</li></orgName></list><tree><noCountry><name sortKey="Romero Gomez, Manuel" sort="Romero Gomez, Manuel" uniqKey="Romero Gomez M" first="Manuel" last="Romero-Gomez">Manuel Romero-Gomez</name></noCountry><country name="France"><region name="Île-de-France"><name sortKey="Ratziu, Vlad" sort="Ratziu, Vlad" uniqKey="Ratziu V" first="Vlad" last="Ratziu">Vlad Ratziu</name></region><name sortKey="Bedossa, Pierre" sort="Bedossa, Pierre" uniqKey="Bedossa P" first="Pierre" last="Bedossa">Pierre Bedossa</name><name sortKey="Boursier, Jerome" sort="Boursier, Jerome" uniqKey="Boursier J" first="Jérôme" last="Boursier">Jérôme Boursier</name><name sortKey="Hanf, Remy" sort="Hanf, Remy" uniqKey="Hanf R" first="Remy" last="Hanf">Remy Hanf</name><name sortKey="Hum, Dean" sort="Hum, Dean" uniqKey="Hum D" first="Dean" last="Hum">Dean Hum</name><name sortKey="Megnien, Sophie" sort="Megnien, Sophie" uniqKey="Megnien S" first="Sophie" last="Megnien">Sophie Megnien</name><name sortKey="Roudot, Alice" sort="Roudot, Alice" uniqKey="Roudot A" first="Alice" last="Roudot">Alice Roudot</name><name sortKey="Serfaty, Lawrence" sort="Serfaty, Lawrence" uniqKey="Serfaty L" first="Lawrence" last="Serfaty">Lawrence Serfaty</name><name sortKey="Staels, Bart" sort="Staels, Bart" uniqKey="Staels B" first="Bart" last="Staels">Bart Staels</name></country><country name="États-Unis"><region name="Texas"><name sortKey="Harrison, Stephen A" sort="Harrison, Stephen A" uniqKey="Harrison S" first="Stephen A" last="Harrison">Stephen A. Harrison</name></region><name sortKey="Abdelmalek, Manal" sort="Abdelmalek, Manal" uniqKey="Abdelmalek M" first="Manal" last="Abdelmalek">Manal Abdelmalek</name><name sortKey="Caldwell, Steve" sort="Caldwell, Steve" uniqKey="Caldwell S" first="Steve" last="Caldwell">Steve Caldwell</name><name sortKey="Sanyal, Arun" sort="Sanyal, Arun" uniqKey="Sanyal A" first="Arun" last="Sanyal">Arun Sanyal</name></country><country name="Belgique"><noRegion><name sortKey="Francque, Sven" sort="Francque, Sven" uniqKey="Francque S" first="Sven" last="Francque">Sven Francque</name></noRegion><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name></country><country name="Pays-Bas"><region name="Gueldre"><name sortKey="Drenth, Joost" sort="Drenth, Joost" uniqKey="Drenth J" first="Joost" last="Drenth">Joost Drenth</name></region></country><country name="Royaume-Uni"><noRegion><name sortKey="Anstee, Quentin M" sort="Anstee, Quentin M" uniqKey="Anstee Q" first="Quentin M" last="Anstee">Quentin M. Anstee</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002007 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002007 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26874076
|texte= Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26874076" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |